medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 1

<< Back Next >>

Rev Mex Urol 2020; 80 (1)

Efficacy of transcutaneous vs percutaneous tibial nerve stimulation in non-neurogenic overactive bladder

Ayala-Quispe VB, Guerrero-Reyes G, Gutiérrez-González A, Hernández-Velázquez R, Moysén-Marín CM, Barragán-Ochoa C

Language: Spanish
References: 36
Page: 1-18
PDF size: 621.78 Kb.


ABSTRACT

Background: Overactive bladder treatment includes lifestyle changes, physical therapy, anticholinergics, neuromodulation, and botulinum toxin. Due to treatment refractoriness, there has been increasing interest in peripheral neuromodulation. Our aim was to evaluate the efficacy of transcutaneous vs percutaneous tibial nerve stimulation in non-neurogenic overactive bladder.
Material and Methods: A randomized clinical trial was conducted on 61 patients, within the time frame of January-October 2019. The patients were divided into two groups: transcutaneous (n=33) and percutaneous (n=28). The stimulator (BioTENS) was utilized at 10 Hz/200 us to apply 12 20-minute sessions. Efficacy was evaluated through a 3-day bladder diary, symptom and quality of life questionnaire, and treatment benefit scale in sessions 1, 6, and 12. Descriptive statistics and correlation of variables were performed using the SPSS v22.0 program, and statistical significance was set at a p ≤ 0.05.
Results: Mean patient age was 66 years. Diurnal and nocturnal urinary frequency decreased, mean urinary volume increased, and the number of urgency and urge incontinence episodes decreased, with no statistically significant differences between the two treatments. The perception of quality of life and improvement related to treatment increased positively with both techniques (p≥0.05). There were no side effects and treatment adherence was 83.6 % (n=51). A lower intensity level was employed in the percutaneous treatment (4 mA vs 7 mA; p=0.0001).
Conclusions: Non-inferiority was demonstrated in this first randomized clinical trial conducted in Mexico that evaluated the efficacy of the two techniques.


REFERENCES

  1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26. doi: 10.1007/s00192-009-0976-9

  2. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. A community-based epidemiological survey of female urinary incontinence: The Norwegian EPINCONT Study. J Clin Epidemiol. 2000;53(11):1150–7. doi: 10.1016/S0895- 4356(00)00232-8

  3. García-Sánchez D, Gutiérrez-González A, Pérez- Ortega R, Gastelum-Félix L, Reyes-Gutiérrez M. Frecuencia de la vejiga hiperactiva en médicos generales. Rev Mex Urol. 2014;74(2):84–7.

  4. Pratt TS, Suskind AM. Management of Overactive Bladder in Older Women. Curr Urol Rep. 2018;19(11):92. doi: 10.1007/s11934-018- 0845-5

  5. Alfonso Barrera E, González Nuño M, Tena- Dávila Mata C, Valiente del Pozo A, Gago Blanco H, Usandizaga Elio R. Eficacia de la estimulación percutánea versus transcutánea del nervio tibial posterior en pacientes con vejiga hiperactiva. Rehabilitación. 2014;48(3):168–74. doi: 10.1016/j.rh.2013.11.003

  6. de Wall LL, Heesakkers JP. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Res Rep Urol. 2017; 9:145–57. doi: 10.2147/RRU. S124981

  7. Elser DM. Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management. Postgrad Med. 2012;124(3):42–9. doi: 10.3810/ pgm.2012.05.2547

  8. Vandoninck V, Balken MR van, Agrò EF, Heesakkers JPFA, Debruyne FMJ, Kiemeney LALM, et al. Posterior tibial nerve stimulation in the treatment of voiding dysfunction: Urodynamic data. Neurourol Urodyn. 2004;23(3):246–51. doi: 10.1002/nau.10158

  9. Ramírez-García I, Blanco-Ratto L, Kauffmann S, Carralero-Martínez A, Sánchez E. Efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome: Randomized control trial. Neurourol Urodyn. 2019;38(1):261–8. doi: 10.1002/nau.23843

  10. Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur Urol. 2018;73(4):596–609. doi: 10.1016/j. eururo.2017.12.031

  11. Stewart F, Gameiro LF, Dib RE, Gameiro MO, Kapoor A, Amaro JL. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. Cochrane Database Syst Rev. 2016;(12). doi: 10.1002/14651858.CD010098. pub4

  12. Mcguire EJ, Shi-chun Z, Horwinski ER, Lytton B. Treatment of Motor and Sensory Detrusor Instability by Electrical Stimulation. J Urol. 1983;129(1):78–9. doi: 10.1016/S0022- 5347(17)51928-X

  13. Stoller M. Afferent stimulation for pelvic floor dysfunction. Eur Urol. 1999;35(2):1–16.

  14. van Balken MR. Percutaneous tibial nerve stimulation: the Urgent PC® device. Expert Review of Medical Devices. 2007;4(5):693–8. doi: 10.1586/17434440.4.5.693

  15. Pérez-Martínez C, Vargas Díaz, IB, & Cristóbal de León-Jaen S. Posible mecanismo de acción de la neuromodulación tibial en la hiperactividad del detrusor. Papel de las interneuronas. Rev Mex Urol. 2016;76(4)

  16. Martínez CP, Palacios-Galicia JL, Vargas-Díaz IB, Cruz-Gómez Y, García-Sánchez D. Efecto de la electroestimulación del nervio tibial en la musculatura del piso pélvico de pacientes con síndrome de vejiga hiperactiva. Rev Mex Urol. 2019;79(4):1–11.

  17. Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo-controlled trial. J Urol. 2010;184(5):2001–6. doi: 10.1016/j. juro.2010.06.113

  18. Rodríguez Martín JM. Electroterapia en Fisioterapia. 3ª. España: Médica Panamericana S.A.; 2013. 662 p.

  19. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW, CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295(10):1152–60. doi: 10.1001/ jama.295.10.1152

  20. Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome. World J Urol. 2014;32(1):179–84. doi: 10.1007/s00345-013-1112-5

  21. Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, et al. Randomized trial of percutaneous tibial nerve stimulation versus eextended releasetolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61. doi: 10.1016/j.juro.2009.05.045

  22. Ammi M, Chautard D, Brassart E, Culty T, Azzouzi AR, Bigot P. Transcutaneous posterior tibial nerve stimulation: evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder. Int Urogynecol J. 2014;25(8):1065–9. doi: 10.1007/s00192-014-2359-0

  23. Martin-Garcia M, Crampton J. A singleblind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS). Physiotherapy. 2019;105(4):469–75. doi: 10.1016/j.physio.2018.12.002

  24. Manríquez V, Guzmán R, Naser M, Aguilera A, Narvaez S, Castro A, et al. Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial. Eur J Obstet Gynecol Reprod Biol. 2016; 196:6–10. doi: 10.1016/j.ejogrb.2015.09.020

  25. Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J. 2010;21(9):1065–70. doi: 10.1007/s00192-010- 1165-6

  26. Secretaria de Gobernación. Informa Conapo sobre la esperanza de vida de la población mexicana. gob.mx. 2019. http://www.gob. mx/segob/prensa/informa-conapo-sobre-laesperanza- de-vida-de-la-poblacion-mexicana

  27. Levin PJ, Wu JM, Kawasaki A, Weidner AC, Amundsen CL. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. Int Urogynecol J. 2012;23(11):1591–7. doi: 10.1007/s00192-012-1712-4

  28. Vandoninck V, Balken MR van, Agrò EF, Petta F, Micali F, Heesakkers JPFA, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: Urodynamic data. Neurourology and Urodynamics. 2003;22(3):227–32. doi: 10.1002/nau.10111

  29. Errando-Smet C, Ruiz MA, Villacampa-Aubá F, Arlandis-Guzmán S, Rejas J, Ruiz L, et al. Adaptación cultural al español y validación psicométrica de la Escala de Beneficio del Tratamiento (Treatment Benefit Scale –TBS) en el tratamiento sintomático de la vejiga hiperactiva. Med Clin (Barc). 2013;140(1):6– 13. doi: 10.1016/j.medcli.2011.11.013

  30. Macías-Vera N, Velázquez-Castellanos P, Godoy-Rodríguez N. Estimulación transcutánea del nervio tibial posterior versus darifenacina para el tratamiento de vejiga hiperactiva refractaria en mujeres. Rev Mex Urol. 2016;76(1)

  31. Maya-Martín J, Albornoz-Cabello M. Estimulacion Electrica Transcutanea y Neuromuscular. 1st ed. España: Elsevier; 2010. 195 p.

  32. Simó M, Porta O, Pubill J, Castillo MT, Mora I, Huguet E, et al. Adherence to fesoterodine in women with overactive bladder in routine clinical practice. Actas Urológicas Españolas (English Edition). 2015;39(4):222–8. doi: 10.1016/j.acuroe.2015.03.005

  33. Chapple C, Sievert K-D, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56. doi: 10.1016/j.eururo.2013.04.001

  34. Valles-Antuña C, Pérez-Haro ML, González- Ruiz de L C, Quintás-Blanco A, Tamargo-Diaz EM, García-Rodríguez J, et al. Estimulación transcutánea del nervio tibial posterior en el tratamiento de la incontinencia urinaria de urgencia refractaria, de origen idiopático y neurógenico. Actas Urol Esp. 2017;41(7):465– 70. doi: 10.1016/j.acuro.2017.01.009

  35. Preyer O, Umek W, Laml T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, et al. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015; 191:51–6. doi: 10.1016/j. ejogrb.2015.05.014

  36. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;(1):CD003974. doi: 10.1002/14651858.CD003974.pub3




2020     |     www.medigraphic.com